Zymeworks Inc. (NASDAQ:ZYME - Get Free Report) insider Paul Moore sold 39,741 shares of the stock in a transaction on Friday, November 13th. The stock was sold at an average price of $26.07, for a total value of $1,036,047.87. Following the completion of the sale, the insider directly owned 33,756 shares in the company, valued at approximately $880,018.92. This represents a 54.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Zymeworks Price Performance
ZYME stock opened at $26.24 on Monday. Zymeworks Inc. has a twelve month low of $18.20 and a twelve month high of $31.97. The business's 50-day moving average price is $27.32 and its 200-day moving average price is $25.48. The stock has a market cap of $1.81 billion, a P/E ratio of 50.46 and a beta of 1.32.
Zymeworks (NASDAQ:ZYME - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported $2.28 EPS for the quarter, topping analysts' consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The firm had revenue of $512.92 million for the quarter, compared to analysts' expectations of $227.40 million. During the same period in the prior year, the business posted ($0.26) earnings per share. The business's revenue for the quarter was up 828.7% on a year-over-year basis. On average, equities research analysts expect that Zymeworks Inc. will post 1.31 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the company. Wolfe Research started coverage on Zymeworks in a report on Thursday, September 17th. They set an "outperform" rating for the company. Truist Financial increased their price target on Zymeworks from $35.00 to $36.00 and gave the stock a "buy" rating in a research note on Tuesday, November 10th. TD Cowen boosted their target price on Zymeworks from $34.00 to $39.00 and gave the stock a "buy" rating in a report on Tuesday, November 10th. Deutsche Bank set a $32.00 price target on Zymeworks in a research note on Wednesday, August 26th. Finally, Stifel Nicolaus set a $46.00 price objective on shares of Zymeworks in a report on Friday, August 7th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $43.25.
Read Our Latest Report on ZYME
Hedge Funds Weigh In On Zymeworks
Large investors have recently added to or reduced their stakes in the company. Nykredit A S acquired a new stake in shares of Zymeworks during the second quarter worth about $25,000. Sterling Capital Management LLC increased its stake in shares of Zymeworks by 813.3% in the third quarter. Sterling Capital Management LLC now owns 1,507 shares of the company's stock valued at $40,000 after buying an additional 1,342 shares during the period. State of Wyoming bought a new stake in shares of Zymeworks in the 2nd quarter valued at $73,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Zymeworks during the 3rd quarter worth approximately $96,000. Finally, State of Alaska Department of Revenue acquired a new stake in Zymeworks in the third quarter valued at approximately $102,000. Institutional investors and hedge funds own 92.89% of the company's stock.
Zymeworks News Summary
Here's some of the latest news about ZYME:
- Positive Sentiment: Citizens JMP raised its price target to $39 from $32 and assigned a “market outperform” rating, implying substantial upside from the referenced $26.24 share price. TickerReport article
- Positive Sentiment: A report linked Zymeworks’ improved outlook to a milestone payment and a profitable quarter. The company’s latest reported results also beat the cited EPS consensus slightly, while revenue was well above estimates—supportive news, though milestone revenue may not recur. Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
- Negative Sentiment: HC Wainwright cut its estimates across several upcoming quarters, lowering its FY2026 EPS forecast to $1.19 from $1.51 and moving its FY2027 outlook from $1.32 profit to a projected $0.39 loss. The analyst retained a Buy rating and $56 target, but the revisions signal a less favorable earnings outlook beyond the recent quarter.
Zymeworks Company Profile
(
Get Free Report)
Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company's lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.